MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the pricing of an underwritten offering of 5,263,156 shares of its common stock, together with accompanying warrants to purchase up to 5,263,156 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.50 per share of common stock, will be exercisable commencing six months following the issue date and will expire five years and 6 months after the date of issuance.

All of the shares of common stock and the accompanying warrants are being offered by Annovis. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the offering.

Before deducting the underwriting discounts and commissions and other offering expenses, Annovis expects to receive total gross proceeds of approximately $10 million, excluding potential proceeds from the exercise of the warrants. The offering is expected to close on or about April 10, 2026, subject to the satisfaction of customary closing conditions.

Canaccord Genuity is acting as the sole bookrunner for the offering.

Annovis intends to use the net proceeds from the offering for the continued clinical development of its lead compound buntanetap in a Phase 3 study for Alzheimer’s disease, and for working capital and general corporate purposes. The shares and accompanying warrants are being offered by Annovis pursuant to a shelf registration statement on Form S-3 (Registration No. 333-276814), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. The offering is being made only by means of a prospectus supplement that forms a part of the registration statement. A prospectus supplement and an accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained, when available, by contacting Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, 30^th Floor, Boston, Massachusetts 02109, or by email at prospectus@cgf.com.